Use of statins in lower extremity artery disease: a review

BackgroundLower extremity artery disease (LE-PAD) is one of the most common manifestations of atherosclerosis, particularly in elderly patients, and it is related to a high cardiovascular risk.DescriptionIt is well established that statin therapy is characterized by crucial benefits on cardiovascular system by limiting atherosclerotic progression and reducing cardiovascular events and mortality. A growing body of evidence support efficacy of statins in LE-PAD due to the ability of both reducing cardiovascular risk and improving walking distance and, hence, quality of life. Consequently, statin therapy should be considered in all LE-PAD patients and new LDL-cholesterol targets should be reached.ConclusionsOur opinion is that statin therapy remains still underutilized or with inadequate dosage, so therapy of LE-PAD patients should be improved to obtain all the demonstrated benefits of statins.

• Publication year

  2012

• Venue

  BMC Surgery

• Publication date

  2012-11-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/1471-2482-12-S1-S15PMID 23173874PMCID 3499199
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cardiac side effects of chemotherapy: state of art and strategies for a correct management.

  2014cited by this paper
• Effects of successful percutaneous lower extremity revascularization on cardiovascular outcome in patients with peripheral arterial disease.

  2013cited by this paper
• ESC Guidelines on the Diagnosis and Treatment of Peripheral Artery Diseases

  2012cited by this paper
• Inhibition of miR-92a increases endothelial proliferation and migration in vitro as well as reduces neointimal proliferation in vivo after vascular injury

  2012cited by this paper
• Femoral plaque echogenicity and cardiovascular risk in claudicants.

  2012cited by this paper
• Cardiovascular effects of treadmill exercise in physiological and pathological preclinical settings.

  2011cited by this paper
• Comparison of effects of statin use on mortality in patients with peripheral arterial disease with versus without elevated C-reactive protein and d-dimer levels.

  2010cited by this paper
• Drug therapy for improving walking distance in intermittent claudication: a systematic review and meta-analysis of robust randomised controlled studies.

  2009cited by this paper
• MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals : a randomised placebo-controlled trial.

  2008cited by this paper
• The rationale for using HMG-CoA reductase inhibitors ('statins') in peripheral arterial disease.

  2007cited by this paper
• Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes: The Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)

  2006influential reference
• Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease.

  2006cited by this paper
• Efficacy and Safety of Atorvastatin in the Prevention of Cardiovascular End Points in Subjects With Type 2 Diabetes

  2006cited by this paper
• Statin therapy improves cardiovascular outcome of patients with peripheral artery disease.

  2004cited by this paper
• Cholesterol Reduction With Atorvastatin Improves Walking Distance in Patients With Peripheral Arterial Disease

  2003cited by this paper
• Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease.

  2003cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial. Commentary

  2002cited by this paper
• Frequency of new coronary events in older persons with peripheral arterial disease and serum low-density lipoprotein cholesterol > or = 125 mg/dl treated with statins versus no lipid-lowering drug.

  2002cited by this paper
• Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21 ras Activation

  2002cited by this paper
• Effects of Balloon Injury on Neointimal Hyperplasia in Streptozotocin-Induced Diabetes and in Hyperinsulinemic Nondiabetic Pancreatic Islet–Transplanted Rats

  2001cited by this paper
• Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury.

  2000cited by this paper
• Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S).

  1998cited by this paper
• Mechanisms of restenosis after angioplasty and approach to therapy (Review).

  1998cited by this paper
• Activation of cAMP–PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury

  1997cited by this paper
• Effect of pravastatin on progression and regression of coronary atherosclerosis and vessel wall changes in carotid and femoral arteries: a report from the Regression Growth Evaluation Statin Study.

  1995cited by this paper
• Inhibition of cellular ras prevents smooth muscle cell proliferation after vascular injury in vivo

  1995cited by this paper
• An accurate stepwise electrocardiographic algorithm for localization of accessory pathways in patients with Wolff-Parkinson-White syndrome from a comprehensive analysis of delta waves and R/S ratio during sinus rhythm.

  1995cited by this paper

• Effects of additional exercise therapy after a successful vascular intervention for people with symptomatic peripheral arterial disease.

  2024cites this paper
• 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases.

  2024cites this paper
• Effects of statin use on primary patency, mortality, and limb loss in patients undergoing lower-limb arterial angioplasty: a systematic review and meta-analysis

  2022cites this paper
• Effects of additional exercise therapy after a successful vascular intervention for patients with symptomatic peripheral arterial disease

  2021cites this paper
• Forty‐eight weeks of statin therapy for type 2 diabetes mellitus patients with lower extremity atherosclerotic disease: Comparison of the effects of pitavastatin and atorvastatin on lower femoral total plaque areas

  2020cites this paper
• 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed b

  2018cites this paper
• Guía ESC 2017 sobre el diagnóstico y tratamiento de la enfermedad arterial periférica, desarrollada en colaboración con la European Society for Vascular Surgery (ESVS)

  2018cites this paper
• Editor's Choice - 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS).

  2018cites this paper
• Lipid‐lowering treatment in peripheral artery disease

  2018cites this paper
• Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases , in collaboration with the European Society for Vascular Surgery ( ESVS ) – Web Addenda

  2017cites this paper
• COPART Risk Score Predicts Long-term Mortality in Peripheral Arterial Occlusive Disease.

  2015cites this paper
• Statins and peripheral arterial disease.

  2015cites this paper
• Consensus Document on Intermittent Claudication from the Central European Vascular Forum (C.E.V.F.)-3rd revision (2013) with the sharing of the Mediterranean League of Angiology and Vascular Surgery, and the North Africa and Middle East Chapter of International Union of Angiology.

  2014cites this paper
• Non-invasive vulnerable plaque imaging: how do we know that treatment works?

  2014cites this paper
• Effect of simvastatin treatment on plasma visfatin levels in obese women

  2014cites this paper
• Physical activity in the prevention of peripheral artery disease in the elderly

  2014cites this paper
• Metabolic syndrome and non-cardiac vascular diseases: an update from human studies.

  2014cites this paper
• Atherosclerotic Peripheral Artery Disease: Clinical Management

  2014cites this paper
• [Lipid lowering therapy in geriatric patients].

  2013cites this paper
• Untersuchungen zur Progenitorzell-vermittelten endothelialen Regeneration im Carotid injury-Modell der Maus

  2013cites this paper
• Lipidtherapie beim geriatrischen Patienten

  2013cites this paper
• Pravastatin stimulates angiogenesis in a murine hindlimb ischemia model: a positron emission tomography imaging study with (64)Cu-NOTA-TRC105.

  2013influential citation
• Transradial approach for the endovascular treatment of type I endoleak after aortic aneurysm repair: a case report

  2013cites this paper
• Lipidsenkende Therapie bei geriatrischen Patienten

  2013cites this paper
• Effect of Surgical Treatment on Lipid Peroxidation Parameters and Antioxidant Status in the Serum of Patients with Peripheral Arterial Disease

  2013cites this paper